NVO - Newly Listed Obesity Player Fractyl Health Shares Encouraging Preclinical Data | Benzinga
Tuesday, Fractyl Health Inc (NASDAQ:GUTS) released new preclinical findings for the first clinical candidate in its Rejuva pancreatic gene therapy platform.
RJVA-001 is the company’s first GLP-1 gene therapy candidate to emerge from the platform, setting the stage for a potentially transformative approach to treating metabolic diseases, including obesity and T2D.
Related Content: Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO.
“As we advance our Rejuva program through preclinical development, we now observe that a single-dose administration ...